

UCLA

Proceedings of UCLA Health

Title

Immune Thrombocytopenic Purpura in a Pregnant Patient

Permalink

<https://escholarship.org/uc/item/4pb75627>

Journal

Proceedings of UCLA Health, 16(1)

Authors

Liu, Kenneth

Yang, Henry

Publication Date

2012-11-05

CLINICAL VIGNETTE

Immune Thrombocytopenic Purpura in a Pregnant Patient

Kenneth Liu, M.D. and Henry Yang, M.D.

Case Report

A 25-year-old Hispanic female with no significant past medical history was referred to our institution for evaluation of thrombocytopenia in the setting of pregnancy. She initially presented to an outside facility complaining of "abdominal movement" and was found to have a 19-week intrauterine pregnancy. She reported gum bleeding brushing her teeth, as well as occasional blood clots from her nose after sneezing for the last two weeks. She denied any personal or family history of bleeding disorders and was taking no medications other than prenatal vitamins.

On physical exam, the patient had normal vital signs. There was neither gum bleeding nor petechiae on exam. Her pulmonary and cardiovascular examination was unremarkable and her abdominal examination was consistent with a 19-week pregnancy.

Laboratory evaluation revealed WBC of 7.8×10^9 /L, hemoglobin of 11.7 g/dL, and platelets of 23×10^9 /L. Liver function tests were within normal limits. Hepatitis panel, HIV, RPR and ANA were negative. The peripheral smear showed markedly decreased number of platelets with occasional large platelets.

The patient was treated as immune thrombocytopenic purpura (ITP) and initiated on oral prednisone at a dose of 1 mg/kg/day. She was monitored as an inpatient for 3 days and at the time of discharge, her platelet count had improved to 51×10^9 /L. Two days later, her platelet count had increased to 145×10^9 /L.

Discussion

Thrombocytopenia is defined as a platelet count of less than 150×10^9 /L and is a common laboratory finding during pregnancy. As many as 10% of pregnant patients are thrombocytopenic at some point during pregnancy. The majority occurs during the third trimester as gestational thrombocytopenia. Most of these patients do not have a prior history of thrombocytopenia and present with low platelet counts for the first time during pregnancy. Patients are usually asymptomatic and have mild

thrombocytopenia, with platelet counts generally above 50×10^9 /L. However, when patients present with very low platelet counts and/or signs of bleeding, therapy is typically initiated¹.

The diagnostic workup of thrombocytopenia during pregnancy is very similar to that in a non-pregnant patient. A complete history and physical examination is important, with particular attention to any medication that may suggest an etiology of the low platelet count. The presence of symptoms may determine the aggressiveness of potential therapy. A complete blood count should be obtained and followed frequently, especially if thrombocytopenia is severe and/or causes symptoms. A peripheral blood smear is also indicated to corroborate the machine count and evaluate other morphologic abnormalities, such as schistocytes. Comprehensive metabolic panel, PT, PTT, hepatitis serologies, HIV and ANA titer are helpful to determine whether the low platelet count is associated with any particular syndrome and to rule out other causes of thrombocytopenia².

The differential diagnosis of thrombocytopenia in a pregnant patient is broad and includes immune thrombocytopenic purpura (ITP), gestational thrombocytopenia, preeclampsia, HELLP syndrome, thrombotic thrombocytopenic purpura (TTP), disseminated intravascular coagulation (DIC), systemic lupus erythematosus (SLE), viral infection, and medication use³. The diagnoses of preeclampsia, HELLP syndrome, TTP, DIC, SLE can generally be established with the combination of physical examination findings, evaluation of peripheral blood smear, and a review of laboratory results such as liver function tests and antinuclear antibodies. Gestational thrombocytopenia is a mild incidental form of thrombocytopenia (typically a platelet count above 70×10^9 /L) associated with pregnancy. Its etiology is not entirely clear, although it is thought to be related to relative hemodilution during pregnancy and accelerated clearance of platelets²⁻⁴.

In contrast, ITP is a diagnosis of exclusion and describes the action of anti-platelet antibodies on platelet glycoproteins, resulting in a decrease in platelet count³. The clinical presentation of patients with ITP ranges from absence of symptoms to symptoms such as petechiae, epistaxis, or gum bleeding. ITP may be clinically indistinguishable from gestational thrombocytopenia. In general, the onset of thrombocytopenia prior to 28 weeks gestation and a platelet count below 50×10^9 /L strongly suggest ITP⁵. Extensive laboratory testing to distinguish gestational thrombocytopenia from ITP is unnecessary since treatment for presumed ITP is typically initiated based on platelet count and symptoms. Bone marrow biopsy and anti-platelet immunoglobulin measurements are not recommended².

The management of ITP in pregnancy is similar to that in other adult patient populations. However, the potential risks of the treatment in the developing fetus must be considered. As with other patients, the treatment for ITP involves corticosteroids, intravenous immunoglobulin (IVIg), and splenectomy^{2,6}. IV anti-D has also been shown to be effective⁷. TPO-receptor agonists and cytotoxic agents such as cyclophosphamide and vinca alkaloids are contraindicated during pregnancy given the potential teratogenic risks. The use of rituximab and azathioprine for ITP during pregnancy has not been evaluated and is generally avoided. The method of delivery of the fetus should be based on obstetric indications. There are currently no randomized studies to determine the optimal platelet thresholds for delivery^{2,6}.

Corticosteroids

As in non-pregnant patients, the administration of corticosteroids is considered to be first-line treatment for ITP during pregnancy^{2,6}. Short-term corticosteroids are generally safe to use during pregnancy, though hypertension, gestational diabetes mellitus and post-partum psychiatric disorders may be exacerbated^{3,6}. A starting dose of 1mg/kg/day (based on pre-pregnancy weight) is typically used⁸, although some have advocated starting at a lower dose ($10\text{--}20$ mg/day)². The initial dose is then slowly tapered to the minimum dose that can maintain an adequate platelet count. Tapering should not be too rapid in the last few weeks just before delivery in order to avoid potential bleeding complications².

IVIg

IVIg may be used if corticosteroids therapy is ineffective or causes significant side effects^{2,6}. In

addition, some experts suggest high-dose IVIg (2 gm/kg) as a potential first-line therapy³. No randomized trials have compared IVIg to corticosteroid therapy for ITP during pregnancy, although response rates are noted to be similar to those in the non-pregnant population². IVIg provides a rapid rise in the platelet count and may be considered for significant bleeding or during delivery. However, multiple courses of IVIg may have to be administered since responses are typically transient³.

Splenectomy

If a patient fails first-line therapy, splenectomy is an option. However, the procedure may lead to preterm labor if performed in the first trimester and may be technically difficult in the third trimester given the increased size of the uterus³. Data on the magnitude of splenectomy risks and on laparoscopic splenectomy are lacking⁹. If the procedure must be performed, appropriate vaccination during or after pregnancy should be administered².

Refractory ITP

Patients who fail to respond to the above conventional therapies may respond to higher doses of corticosteroids and IVIg (methylprednisolone 1 gram, IVIg 1-2 gm/kg) in combination^{2,3}. IV anti-D at 50-75 µg/kg has been used in non-splenectomized Rh(D)-positive patients and shown to be effective⁷. Rituximab and azathioprine have been used during pregnancy for indications other than ITP without significant toxicity^{10,11}. Clinicians should carefully weigh the potential risks and benefits of cytotoxic agents during pregnancy.

Conclusion

Thrombocytopenia is not an uncommon finding in pregnancy. When it occurs, it is important to evaluate the patient thoroughly and determine what intervention, if any, is appropriate after weighing the risks and benefits of each potential treatment. In this case, our patient was diagnosed with probable immune thrombocytopenia purpura. Given the platelet count was quite low at 23×10^9 /L and the patient was symptomatic, oral prednisone at 1 mg/kg/day was initiated. The patient's platelet count

responded appropriately, and corticosteroid therapy was eventually tapered.

REFERENCES

1. **Parnas M, Sheiner E, Shoham-Vardi I, Burstein E, Yermiahu T, Levi I, Holcberg G, Yerushalmi R.** Moderate to severe thrombocytopenia during pregnancy. *Eur J Obstet Gynecol Reprod Biol.* 2006 Sep-Oct;128(1-2):163-8. Epub 2006 Mar 13. PubMed PMID: 16533554.
2. **Provan D, Stasi R, Newland AC, Blanchette VS, Bolton-Maggs P, Bussel JB, Chong BH, Cines DB, Gernsheimer TB, Godeau B, Grainger J, Greer I, Hunt BJ, Imbach PA, Lyons G, McMillan R, Rodeghiero F, Sanz MA, Tarantino M, Watson S, Young J, Kuter DJ.** International consensus report on the investigation and management of primary immune thrombocytopenia. *Blood.* 2010 Jan 14;115(2):168-86. Epub 2009 Oct 21. Review. PubMed PMID: 19846889.
3. **McCrae KR.** Thrombocytopenia in pregnancy: differential diagnosis, pathogenesis, and management. *Blood Rev.* 2003 Mar;17(1):7-14. Review. Erratum in: *Blood Rev.* 2003 Dec;17(4):265. PubMed PMID: 12490206.
4. **Shehata N, Burrows R, Kelton JG.** Gestational thrombocytopenia. *Clin Obstet Gynecol.* 1999 Jun;42(2):327-34. Review. PubMed PMID: 10370851.
5. **Kwon JY, Shin JC, Lee JW, Lee JK, Kim SP, Rha JG.** Predictors of idiopathic thrombocytopenic purpura in pregnant women presenting with thrombocytopenia. *Int J Gynaecol Obstet.* 2007 Feb;96(2):85-8. Epub 2007 Jan 18. PubMed PMID: 17239378.
6. **Neunert C, Lim W, Crowther M, Cohen A, Solberg L Jr, Crowther MA;** American Society of Hematology. The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. *Blood.* 2011 Apr 21;117(16):4190-207. Epub 2011 Feb 16. Review. PubMed PMID: 21325604.
7. **Michel M, Novoa MV, Bussel JB.** Intravenous anti-D as a treatment for immune thrombocytopenic purpura (ITP) during pregnancy. *Br J Haematol.* 2003 Oct;123(1):142-6. PubMed PMID: 14510957.
8. **Bockenstedt PL.** Thrombocytopenia in pregnancy. *Hematol Oncol Clin North Am.* 2011 Apr;25(2):293-310, vii-viii. Review. PubMed PMID: 21444031.
9. **Felbinger TW, Posner M, Eltzschig HK, Kodali BS.** Laparoscopic splenectomy in a pregnant patient with immune thrombocytopenic purpura. *Int J Obstet Anesth.* 2007 Jul;16(3):281-3. Epub 2007 Mar 30. PubMed PMID: 17399979.
10. **Herold M, Schnohr S, Bittrich H.** Efficacy and safety of a combined rituximab chemotherapy during pregnancy. *J Clin Oncol.* 2001 Jul 15;19(14):3439. PubMed PMID: 11454895.
11. **Alstead EM, Ritchie JK, Lennard-Jones JE, Farthing MJ, Clark ML.** Safety of azathioprine in pregnancy in inflammatory bowel disease. *Gastroenterology.* 1990 Aug;99(2):443-6. PubMed PMID: 2365192.